Iovance Biotherapeutics Soars More Than 20% After Hours on Q2 Beats
$Iovance Biotherapeutics (IOVA.US)$ soared nearly 20% after hours Thursday after the cancer-drug company beat analyst estimates for its Q2 revenues and loss per share.
IOVA gained 19.7% to $9.50 shortly before 4:45 p.m. ET after the company said Q2 sales came in at $31.1 million, reportedly beating analysts' $24.6 million consensus.
Iovance also reported a $0.34 loss per share, besting the $0.35 that published reports showed analysts’ consensus estimate had called for.
The biopharma firm also guided Q3 total product revenue to $53 million-$55 million, exceeding the $24.6 million that analysts had reportedly been expecting.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Director of Financial Content
Former top editor at Seeking Alpha, Fidelity.com, TheStreet.com and UPI.
484Followers
476Following
2549Visitors
Follow